US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Odonate Therapeutics LLC

1.12

+0.0000

Volume:- -

Turnover:- -

Market Cap:43.11M

PE:-0.41

High:1.12

Open:1.12

Low:1.12

Close:1.12

Loading ...

Overview Company News Filings

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial

MindMed Appoints Matt Wiley as Chief Commercial Officer

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Pfizer to Pay $59.7 Million to Resolve Biohaven's Alleged Kickback Scheme for Nurtec ODT

MT Newswires Live

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

ACCESS Newswire

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema

5 Biotech Breakthrough Stocks to Watch in 2025

MindMed to Be Added to the Nasdaq Biotechnology Index

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ODT/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ODT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODT\",,,,,undefined,":{"symbol":"ODT","market":"US","secType":"STK","nameCN":"Odonate Therapeutics LLC","latestPrice":1.12,"timestamp":1647633600000,"preClose":1.12,"halted":0,"volume":0,"delay":0,"floatShares":20627098,"shares":38490336,"eps":-2.711429,"marketStatus":"Pre-Mkt","change":0,"latestTime":"05-01 09:11:15 EDT","open":1.12,"high":1.12,"low":1.12,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.711429,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746106200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1512622800000,"exchange":"NASDAQ","adjPreClose":1.12,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODT\",,,,,undefined,":{"symbol":"ODT","floatShares":20627098,"roa":"-33.09%","roe":"-86.14%","lyrEps":-3.844801,"shares":38490336,"dividePrice":0,"high":1.12,"amplitude":0,"preClose":1.12,"low":1.12,"week52Low":0.85,"pbRate":"0.60","week52High":28.41,"institutionHeld":0,"latestPrice":1.12,"eps":-2.711429,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.711429,"open":1.12,"prevYearClose":1.35},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ODT\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527541636","title":"MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2527541636","media":"Business Wire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527541636?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:00","pubTimestamp":1744714800,"startTime":"0","endTime":"0","summary":"- Emerge is the first Phase 3 study of lysergide D-tartrate  in MDD; primary endpoint will measure change from baseline in Montgomery-sberg Depression Rating Scale  score at Week 6 between MM120 Orally Disintegrating Tablet  100 g and placebo -. - Topline data from the 12-week double-blind period anticipated in the second half of 2026 -. \"In our Phase 2b study, MADRS score improvements after a single MM120 100 g dose were clinically and statistically significant compared to placebo, providing meaningful benefits to participants. Having dosed the first participant in the Phase 3 Emerge study, we are excited for the therapeutic potential that MM120 ODT shows for the 21 million people in the U.S. affected by MDD,\" said Daniel R. Karlin, M.D., M.A., Chief Medical Officer of MindMed. \"By running our MDD and GAD Phase 3 studies concurrently, we can leverage the shared symptomatology between these conditions to more effectively match participants to the appropriate study based on their clinic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-announces-first-patient-dosed-110000855.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNMD","BK4007","ODT","BK4547","ABVC","BK4139"],"gpt_icon":0},{"id":"2522026810","title":"KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2522026810","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522026810?lang=en_us&edition=fundamental","pubTime":"2025-03-25 19:00","pubTimestamp":1742900400,"startTime":"0","endTime":"0","summary":"Initial target enrollment surpassed in fewer than seven months; trial expanded due to high demand. First data presentation expected before year-end; sNDA submission by mid-2026. CAMBRIDGE, Mass. & SALISBURY, England, March 25, 2025----KalVista Pharmaceuticals, Inc.  today announced the completion of enrollment in the open-label KONFIDENT-KID clinical trial of sebetralstat, an investigational, novel, oral plasma kallikrein inhibitor, in pediatric patients between the ages of two and 11 with hereditary angioedema .\"We're proud to share that we achieved target enrollment in our KONFIDENT-KID trial a full year ahead of schedule and expanded the trial size due to overwhelming interest,\" said Ben Palleiko, CEO of KalVista. \"The high level of participation from families living with HAE underscores the significant need for an oral treatment option for this population. Even with this larger trial size, we anticipate that initial results will be shared later this year, with an sNDA expected to b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kalvista-pharmaceuticals-announces-early-completion-110000702.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4198","LU1169590202.USD","LU0205194284.USD","ODT","LU0012050646.USD","LU0106261612.USD","LU0205193047.USD","LU1169589451.USD","IE00B64QTZ34.USD","IE00BLDYK493.USD","BK4139","HAE","BK4007","KALV"],"gpt_icon":0},{"id":"2520541217","title":"MindMed Appoints Matt Wiley as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520541217","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520541217?lang=en_us&edition=fundamental","pubTime":"2025-03-17 19:00","pubTimestamp":1742209200,"startTime":"0","endTime":"0","summary":"NEW YORK, March 17, 2025----Mind Medicine  Inc. , , a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Matt Wiley as its Chief Commercial Officer . In his new role, Mr. Wiley will serve as a member of the executive team, overseeing the Company’s commercial vision and strategy as it prepares for the potential launch of its first product, MM120 orally disintegrating tablet  for generalized anxiety disorder  and major depressive disorder .\"Matt’s deep experience in launching multiple neuroscience and psychiatric therapeutics will be invaluable as we prepare for our first potential FDA approval of MM120 ODT,\" said Rob Barrow, Chief Executive Officer of MindMed. \"His proven track record in driving commercial success for novel, first-in-class products like XYREM will be an asset in realizing the significant commercial potential of MM120. As we approach multiple key clinical readouts from our ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-appoints-matt-wiley-chief-110000560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SQQQ","ODT","LU2357125470.USD","CCO","QLD","BK4009","NVIW.SI","USJW.SI","MNQmain","LU2249611893.SGD","NQmain","LU0823414551.USD","BK4007","MNMD","LU0823414478.USD","TQQQ","BK4547","TSYW.SI","LU2506951792.HKD","QID","USAW.SI","PSQ",".IXIC","LU2294711713.HKD"],"gpt_icon":1},{"id":"2517547871","title":"Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2517547871","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517547871?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:00","pubTimestamp":1741266000,"startTime":"0","endTime":"0","summary":"VOQUEZNA (vonoprazan) generated $55.3 million in 2024 net revenues in its first full year of launch, driven by strong demand, including $29.7 million in Q4, an 81% increase from Q3Over 300,000 filled ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/06/3038128/0/en/Phathom-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0971096721.USD","BK4190","LU1261432733.SGD","LU0170899867.USD","LU2463526074.USD","BK4570","BK4121","BK4006","A","IE00BN0W2T93.GBP","BK4588","IE00BHPRN162.USD","BK4007","PHAT","LU1487256676.USD","IE00BN0W2V16.EUR","LU2041044095.USD","LU2092937221.SGD","LU0149725797.USD","LU1363072403.SGD","LU1721428933.USD","DTC","IE00B1BXHZ80.USD","CP","IE00BZ1G4Q59.USD","BK4136","PPI","IE00BKVL7J92.USD","BK4567","BK4585","LU1543694498.USD","BK4016","LU2413666426.HKD","LU1481600234.SGD","IP","IE00BN0W2W23.USD","LU0882574139.USD","ODT","CMC","LU1481599808.USD","LU1165135440.EUR","LU2413666699.HKD","LU0347712357.USD","LU0267386448.USD"],"gpt_icon":0},{"id":"2517215640","title":"MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2517215640","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517215640?lang=en_us&edition=fundamental","pubTime":"2025-03-06 20:00","pubTimestamp":1741262400,"startTime":"0","endTime":"0","summary":"--First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet  in Generalized Anxiety Disorder ; 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama--. --On track to initiate Emerge, the first Phase 3 study of MM120 ODT in Major Depressive Disorder  in 1H of 2025--. --Raised approximately $250 million in gross proceeds through two equity financings in 2024; cash and cash equivalents of $273.7 million as of December 31, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD--. --Company to host a conference call today at 8:00 a.m. EST--. NEW YORK, March 06, 2025----Mind Medicine  Inc. , , a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its fourth quarter and full year 2024 financial results and provided an update on business highlights.Initiated dosing i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-reports-fourth-quarter-full-120000302.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4213","ODT","BK4585","BK4588","MNMD","APA","BK4547","ABVC","BK4139","LU0256331488.USD","BK4007"],"gpt_icon":0},{"id":"2510859333","title":"KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2510859333","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510859333?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:00","pubTimestamp":1739188800,"startTime":"0","endTime":"0","summary":"– Claims data show 40% of patients on long-term prophylaxis have gaps in prescription refills, leading to greater on-demand use and higher rate of LTP discontinuation-. -Data from KONFIDENT-S show patients on LTP average 1.7 HAE attacks per month and symptom relief for treated attacks in median 1.3 hours -. –Results confirm sebetralstat effective for on-demand treatment of attacks regardless of type of LTP therapy used, including an all-oral regimen–。CAMBRIDGE, Mass. & SALISBURY, England, February 10, 2025----KalVista Pharmaceuticals, Inc. , today announced the presentation of novel data related to long-term prophylaxis and sebetralstat at the Western Society of Allergy, Asthma & Immunology  2025 Annual Meeting taking place in Waimea, HI from February 9-13, 2025.Raffi Tachdjian, MD, MPH, Associate Clinical Professor of Medicine and Pediatrics in the Division of Allergy and Clinical Immunology at the David Geffen School of Medicine at the University of California, Los Angeles , presente","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kalvista-pharmaceuticals-presents-sebetralstat-data-120000097.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0205193047.USD","BK4007","HAE","BK4198","IE00B64QTZ34.USD","LU1169589451.USD","LU0012050646.USD","KALV","LU0106261612.USD","ODT","BK4168","IE00BLDYK493.USD","WRN","BK4139","LU0205194284.USD","LU1169590202.USD"],"gpt_icon":0},{"id":"2507345642","title":"MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2507345642","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507345642?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:00","pubTimestamp":1738238400,"startTime":"0","endTime":"0","summary":"The clinical trial design of the 52-week Panorama study is aligned to Voyage and will be conducted in two parts: Part A, a 12-week, randomized, double-blind, placebo-controlled, parallel-group period; and Part B, a 40-week extension period during which participants will be eligible for open-label treatment with MM120 ODT based on symptom severity. Participants will be randomized 2:1:2 to receive MM120 ODT 100 g, MM120 ODT 50 g, or placebo. The 50 g arm serves to confound participants’ ability to accurately assess the dose condition to which they have been randomized. This approach builds on the MM120 Phase 2b study, which the Company believes demonstrated that the clinical activity of MM120 was not attributable to functional unblinding and aligns with FDA guidance regarding the use of complementary designs across our Phase 2 and 3 studies. The primary endpoint of Panorama will measure the change from baseline in HAM-A at Week 12 between MM120 ODT 100 g and placebo, which is consistent ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-announces-first-patient-dosed-120000222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","MNMD","ODT","BK4547"],"gpt_icon":0},{"id":"2506375098","title":"Pfizer to Pay $59.7 Million to Resolve Biohaven's Alleged Kickback Scheme for Nurtec ODT","url":"https://stock-news.laohu8.com/highlight/detail?id=2506375098","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506375098?lang=en_us&edition=fundamental","pubTime":"2025-01-27 20:01","pubTimestamp":1737979278,"startTime":"0","endTime":"0","summary":"Pfizer  agreed to pay about $59.7 million to settle allegations that Biohaven Pharmaceutical Holding, before being acquired by Pfizer, defrauded several US health care programs by paying kickbacks to doctors to drive prescriptions of its Nurtec ODT drug for migraine, the US Department of Justice said Friday.According to the statement, Biohaven allegedly paid \"improper remuneration\" to healthcare professionals from March 1, 2020, through September 30, 2022, to induce them to prescribe Nurtec ODT and subsequently submit false claims to Medicare and other federal healthcare programs.The Justice Department said the settlement also resolves a suit filed by a former Biohaven sales representative. However, it was noted that the settlement only resolved allegations, and no liability was determined.Pfizer and Biohaven Pharmaceutical Holding did not immediately respond to MT Newswires' requests for comments.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4534","BK4007","LU0289739699.SGD","LU0306806265.USD","IE00BBT3K403.USD","BK4568","LU0234572021.USD","LU0306807586.USD","LU1894683348.USD","IE00BLSP4452.SGD","PFE.AU","IE00BLSP4239.USD","BK4581","IE0002270589.USD","BK4588","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0058720904.USD","LU0225284248.USD","LU0868494617.USD","LU1023059063.AUD","LU1894683264.USD","BK4550","SG9999002224.SGD","SG9999003800.SGD","BK4585","LU0122379950.USD","BK4599","SG9999011175.SGD","IE000M9KFDE8.USD","LU0985481810.HKD","LU0170899867.USD","BK4533","LU1883839398.USD","LU1066051498.USD","ODT","PFE","BK7095","LU0456855351.SGD","SG9999001176.SGD","SG9999013999.USD","BK4592","LU1066053197.SGD","LU0225771236.USD","LU0321505868.SGD","SGXZ57979304.SGD","SG9999002232.USD","LU1057294990.SGD","LU0321505439.SGD","SG9999001176.USD"],"gpt_icon":1},{"id":"2505220756","title":"Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT","url":"https://stock-news.laohu8.com/highlight/detail?id=2505220756","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505220756?lang=en_us&edition=fundamental","pubTime":"2025-01-21 21:00","pubTimestamp":1737464400,"startTime":"0","endTime":"0","summary":"FORT LAUDERDALE, FL / ACCESS Newswire / January 21, 2025 / Sunshine Biopharma Inc.  , a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched two new generic prescription drugs.The newly launched drugs are Olanzapine and Olanzapine ODT. Olanzapine is a generic version of Zyprexa. Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders. Olanzapine is also indicated for the acute treatment of manic or mixed episodes of bipolar I disorder. Nora Pharma's Olanzapine is available in bottles of 100 tablets for the Canadian market in strengths of 2.5mg, 5mg, 7.5mg, 10mg, 15mg and 20mg. Nora Pharma's Olanzapine ODT  is available for the Canadian market in strengths of 5mg, 10mg, 15mg and 20mg in blisters of 30 tablets.In addition, Sunshine Biopharma is conducting a pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sunshine-biopharma-expands-product-line-130000440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ODT","SBFMW","SBFM","BK4007"],"gpt_icon":0},{"id":"2505229913","title":"KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema","url":"https://stock-news.laohu8.com/highlight/detail?id=2505229913","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505229913?lang=en_us&edition=fundamental","pubTime":"2025-01-21 20:00","pubTimestamp":1737460800,"startTime":"0","endTime":"0","summary":"–Orphan drug designation paves the way for potential of sebetralstat to be first oral on-demand treatment for HAE in Japan–。– Submission advances Company’s strategic plan to address unmet needs in HAE on global scale–。\"The submission of our NDA for sebetralstat in Japan represents another key step toward our efforts to make this important new treatment available to as many people living with HAE as possible,\" said Ben Palleiko, CEO of KalVista. \"The Orphan Drug Designation not only acknowledges the critical need for new, effective treatments for HAE in Japan but underscores the potential of sebetralstat to provide meaningful relief for people who have faced ongoing challenges with existing options. We are proud to be at the forefront of advancing care for the HAE community.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kalvista-announces-orphan-drug-designation-120000382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","IE00BLDYK493.USD","KALV","LU0205194284.USD","LU1169590202.USD","LU0205193047.USD","IE00B64QTZ34.USD","BK4198","LU0012050646.USD","ODT","LU1169589451.USD","HAE","LU0106261612.USD","BK4139"],"gpt_icon":0},{"id":"2493675167","title":"5 Biotech Breakthrough Stocks to Watch in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2493675167","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493675167?lang=en_us&edition=fundamental","pubTime":"2024-12-23 22:39","pubTimestamp":1734964740,"startTime":"0","endTime":"0","summary":"After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services.Nonetheless, innovation is at its peak for the industry, with key spaces like diabetes/obesity, gene therapy, inflammation and neuroscience attracting investor attention. FDA approvals continued at a rapid pace throughout 2024. The FDA approved 46 drugs , which is in line with the annual average of 45 to 50 approvals. R&D innovation is likely to remain a major focus area in 2025 as well.In this article, we discuss five of the most enthralling biotech breakthrough stocks for those investors who are looking to diversify away from traditional pharmaceuticals. These stocks are Mind Medicine MNMD, Beam Therapeutics BEAM, Arcellx ACLX, Ocugen OCGN and Insmed INSM. These companies have novel pipeline candidate","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/5-biotech-breakthrough-stocks-watch-143900028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","BK4563","BK4588","ACLX","OCGN","GAINI","INSM","BK4007","LU0320765992.SGD","LU0889565916.HKD","MNMD","LU0053671581.USD","BK4139","BEAM","BK4535","ODT","BK4547","LU0109394709.USD","BK4505","BK4585","BK4556"],"gpt_icon":0},{"id":"2492833121","title":"MindMed to Be Added to the Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492833121","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492833121?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:00","pubTimestamp":1734609600,"startTime":"0","endTime":"0","summary":"NEW YORK, December 19, 2024----Mind Medicine  Inc. , , a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will be added to the Nasdaq Biotechnology Index , effective at market open on Monday, December 23, 2024.\"2024 has been a transformational year for MindMed. We’ve successfully executed many important milestones, including raising approximately $250 million through two equity financings, obtaining a newly issued patent covering MM120 orally disintegrating tablet  and extending intellectual property protection through 2041, expanding our pipeline to include MM120 ODT for major depressive disorder, and most recently, launching Voyage, our Phase 3 study of MM120 ODT in generalized anxiety disorder,\" said Rob Barrow, Chief Executive Officer of MindMed. \"We are in a pivotal phase in our growth and the addition to the NBI further validates our potential in delivering long-term value to shareholders as we p","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/eWlU2A18DIV5.Fny3k24ng--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/387f6e4e380da4e39f13a8e92f42a101","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/eWlU2A18DIV5.Fny3k24ng--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/387f6e4e380da4e39f13a8e92f42a101"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-added-nasdaq-biotechnology-index-120000637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ODT","MNQmain","PSQ","LU2210149790.SGD","IE00BKPKM429.USD","SQQQ","BK4547","IE00B64PRP62.GBP","NVIW.SI","NDAQ","BK4112","USJW.SI","LU2095319765.USD","IE00B3QW5Z07.USD","USAW.SI","NQmain","BK4585","LU2210150020.SGD","TQQQ","QLD","BK4007","IE00BGHQF748.EUR","MNMD","TSYW.SI",".IXIC","QID","ICB","BK4588"],"gpt_icon":1},{"id":"2491667348","title":"MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2491667348","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491667348?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:00","pubTimestamp":1734350400,"startTime":"0","endTime":"0","summary":"- Voyage is the first-ever Phase 3 study of lysergide D-tartrate  with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale  score at week 12 for MM120 Orally Disintegrating Tablet  100 g vs placebo -. - Study builds on positive Phase 2b study results presented at the American Psychiatric Association’s Annual Meeting in May 2024 -. \"It is critical to continue to develop new and effective treatment options for patients with GAD, a debilitating condition where there is an urgent need for transformational innovation,\" said David Feifel, M.D., Ph.D., Professor Emeritus of Psychiatry at the University of California, San Diego and Director of the Kadima Neuropsychiatry Institute in La Jolla, California and an investigator in the Voyage study. \"The design of the MM120 ODT Phase 3 clinical program directly builds on the robust Phase 2b study results and incorporates best-in-class methodologies to mitigate the impact of functional unblinding, including th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vDg8YFRO3BJk1UZJCKDJoQ--~B/aD0zMjA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/02319186c45b083468a9e3c39b6777d1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vDg8YFRO3BJk1UZJCKDJoQ--~B/aD0zMjA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/02319186c45b083468a9e3c39b6777d1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-announces-first-patient-dosed-120000488.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4547","ODT","BK4007","MNMD"],"gpt_icon":0},{"id":"2489458174","title":"MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2489458174","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489458174?lang=en_us&edition=fundamental","pubTime":"2024-12-05 20:00","pubTimestamp":1733400000,"startTime":"0","endTime":"0","summary":"- Innovation Passport Designation Aims to Accelerate Time to Market and Facilitate Patient Access to Innovative Medicines -. \"Receiving the Innovation Passport designation is recognition of MM120 ODT’s potential to address GAD, one of the most critical and underserved needs in mental health,\" said Rob Barrow, Chief Executive Officer of MindMed. \"Following the receipt of Breakthrough Therapy Designation by the U.S. Food and Drug Administration, the Innovation Passport designation underscores our commitment to bringing MM120 ODT to people living with GAD and our dedication to working closely with the MHRA to expedite patient access. We are determined to offer new hope and transformative solutions where current treatments have failed to meet the needs of those who suffer from this serious condition.\"","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/RYsdMxLRbuQD9Zldx11baQ--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/423b9b2984ff1a73b807265e12278e34","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/RYsdMxLRbuQD9Zldx11baQ--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/423b9b2984ff1a73b807265e12278e34"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-awarded-innovation-passport-designation-120000618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNMD","ODT","UK","UBCP"],"gpt_icon":0},{"id":"2488691656","title":"MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2488691656","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488691656?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:00","pubTimestamp":1733227200,"startTime":"0","endTime":"0","summary":"Javier Muniz, M.D. - Vice President of Research and Development Strategy, MindMed . \"Javier’s extensive expertise leading interdisciplinary scientific teams at the U.S. Food and Drug Administration , combined with his deep experience within the uniformed services in the fields of neuroscience and psychiatry makes him a welcome addition to the MindMed team,\" said Dan Karlin, M.D., M.A., Chief Medical Officer of MindMed. \"His leadership will play an important role in strengthening our R&D operations as we advance the therapeutic potential of our pipeline, prepare for two potential approvals and aim to reshape the treatment landscape for people living with brain health disorders.\". \"I am thrilled to join MindMed at such a pivotal moment in the Company’s history, with potential approvals of MM120 ODT for multiple indications on the horizon,\" said Dr. Muniz. \"The groundbreaking science and purpose-driven culture made this a unique and compelling opportunity. I look forward to advancing our ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pB5ebD38OkWo4d7wRd_Jjw--~B/aD00ODA7dz0zMjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c3dcdac07fac564c4b63a1203ddbaeb2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pB5ebD38OkWo4d7wRd_Jjw--~B/aD00ODA7dz0zMjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c3dcdac07fac564c4b63a1203ddbaeb2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-appoints-javier-muniz-m-120000228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNMD","BK4547","BK4007","ODT"],"gpt_icon":0},{"id":"2484562920","title":"MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2484562920","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484562920?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:00","pubTimestamp":1731931200,"startTime":"0","endTime":"0","summary":"NEW YORK, November 18, 2024----Mind Medicine  Inc. , , a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief Regulatory and Quality Assurance Officer. Dr. Pratt will serve as a member of the Executive Committee and oversee the Company’s regulatory and quality functions, as well as its product registration strategies.\"We are thrilled to welcome Gregg to the MindMed team. His leadership will strengthen our capabilities and accelerate our progress as we prepare to launch three Phase 3 studies of MM120 orally disintegrating tablet  in generalized anxiety disorder  and major depressive disorder ,\" said Rob Barrow, Chief Executive Officer of MindMed. \"Gregg’s deep expertise in leading the regulatory approvals of transformative psychiatric drugs—demonstrated by his recent leadership in the approval of the first novel schizophrenia treatment in decades—will be key as we ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/A3Mo21waMUHhpCJ9e1pNMA--~B/aD00ODA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/997f2797aa842b96f66bf77a9fa13132","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/A3Mo21waMUHhpCJ9e1pNMA--~B/aD00ODA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/997f2797aa842b96f66bf77a9fa13132"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-appoints-gregg-pratt-ph-120000384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4547","NQmain","QID","PSQ",".IXIC","SQQQ","TQQQ","MNMD","ODT","BK4007","QLD","MNQmain"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ODT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2022-01-18","symbol":"ODT","reason":null,"defaultRemindTime":1642516200000,"announcedDate":"2022-01-14","type":"delisting","dateTimestamp":1642482000000},{"market":"US","date":"2021-07-27","symbol":"ODT","fiscalQuarterEnding":"2021/06","expectedEps":-0.33,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1627358400000,"reportTimeType":"pre","actualEps":-0.58},{"market":"US","date":"2021-05-14","symbol":"ODT","fiscalQuarterEnding":"2021/03","expectedEps":-0.85,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1620964800000,"reportTimeType":"pre","actualEps":-0.9},{"market":"US","date":"2021-02-23","symbol":"ODT","fiscalQuarterEnding":"2020/12","expectedEps":-0.77,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1614056400000,"reportTimeType":"pre","actualEps":-0.87},{"market":"US","date":"2020-10-28","symbol":"ODT","fiscalQuarterEnding":"2020/09","expectedEps":-1.19,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1603857600000,"reportTimeType":"pre","actualEps":-0.93}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ODT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ODT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ODT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ODT","date":"2022-01-14","current":-0.441221,"percent":0.999019,"low":-4254.803165,"twenty":-51.545461,"median":-12.685823,"eighty":-1.250504,"high":-0.411052,"avg":-199.795306,"sd":788.159007,"marketCap":45033693},"quantilePoints":[{"date":"2020-05-01","current":-7.223679,"twenty":-112.309407,"median":-21.129102,"eighty":-13.151929,"marketCap":818753500},{"date":"2020-05-08","current":-7.826833,"twenty":-111.894338,"median":-20.877007,"eighty":-13.081021,"marketCap":887116690},{"date":"2020-05-15","current":-8.000337,"twenty":-111.542989,"median":-20.705877,"eighty":-13.027804,"marketCap":906782164},{"date":"2020-05-22","current":-8.799237,"twenty":-111.373941,"median":-20.548477,"eighty":-12.918429,"marketCap":997331941},{"date":"2020-05-29","current":-9.255347,"twenty":-111.270635,"median":-20.516455,"eighty":-12.799348,"marketCap":1049028799},{"date":"2020-06-05","current":-10.065579,"twenty":-111.109158,"median":-20.428056,"eighty":-12.750062,"marketCap":1140862970},{"date":"2020-06-12","current":-10.734163,"twenty":-110.746818,"median":-20.383807,"eighty":-12.735476,"marketCap":1216642216},{"date":"2020-06-19","current":-11.759702,"twenty":-110.632012,"median":-20.305487,"eighty":-12.703236,"marketCap":1332879873},{"date":"2020-06-26","current":-11.326256,"twenty":-110.437671,"median":-20.239649,"eighty":-12.646976,"marketCap":1283751803},{"date":"2020-07-02","current":-11.365917,"twenty":-110.411627,"median":-20.121945,"eighty":-12.603772,"marketCap":1288247182},{"date":"2020-07-10","current":-10.963634,"twenty":-110.256351,"median":-19.942216,"eighty":-12.543272,"marketCap":1242651195},{"date":"2020-07-17","current":-11.116615,"twenty":-110.021564,"median":-19.754784,"eighty":-12.471451,"marketCap":1259990514},{"date":"2020-07-24","current":-10.269554,"twenty":-109.739818,"median":-19.561906,"eighty":-12.364243,"marketCap":1163982062},{"date":"2020-07-31","current":-9.896749,"twenty":-109.683845,"median":-19.217934,"eighty":-12.243315,"marketCap":1168459717},{"date":"2020-08-07","current":-10.340294,"twenty":-109.542984,"median":-18.883695,"eighty":-12.192618,"marketCap":1220826760},{"date":"2020-08-14","current":-9.831442,"twenty":-109.49603,"median":-18.672368,"eighty":-12.093993,"marketCap":1160749232},{"date":"2020-08-21","current":-9.12667,"twenty":-109.035455,"median":-18.542025,"eighty":-11.994839,"marketCap":1077540250},{"date":"2020-08-28","current":-5.715581,"twenty":-109.026493,"median":-18.402172,"eighty":-11.759702,"marketCap":674810081},{"date":"2020-09-04","current":-4.769378,"twenty":-108.932585,"median":-18.315022,"eighty":-11.725706,"marketCap":563096555},{"date":"2020-09-11","current":-4.769378,"twenty":-108.902183,"median":-18.214268,"eighty":-11.504583,"marketCap":563096555},{"date":"2020-09-18","current":-4.807737,"twenty":-108.812296,"median":-18.021631,"eighty":-11.451076,"marketCap":567625482},{"date":"2020-09-25","current":-4.270703,"twenty":-108.535916,"median":-17.903148,"eighty":-11.318324,"marketCap":504220508},{"date":"2020-10-02","current":-4.686265,"twenty":-108.434398,"median":-17.778659,"eighty":-11.200409,"marketCap":553283880},{"date":"2020-10-09","current":-5.220103,"twenty":-108.417877,"median":-17.505033,"eighty":-11.044465,"marketCap":616311444},{"date":"2020-10-16","current":-5.101827,"twenty":-108.378532,"median":-17.433302,"eighty":-10.961368,"marketCap":602347253},{"date":"2020-10-23","current":-5.277642,"twenty":-108.218889,"median":-17.376054,"eighty":-10.761926,"marketCap":623104834},{"date":"2020-10-30","current":-4.55361,"twenty":-107.850346,"median":-17.261707,"eighty":-10.696767,"marketCap":555153334},{"date":"2020-11-06","current":-4.490409,"twenty":-107.730035,"median":-17.210961,"eighty":-10.368593,"marketCap":547448221},{"date":"2020-11-13","current":-4.53465,"twenty":-107.638434,"median":-17.16539,"eighty":-10.265021,"marketCap":552841800},{"date":"2020-11-20","current":-4.496729,"twenty":-107.354941,"median":-17.076823,"eighty":-10.061201,"marketCap":548218733},{"date":"2020-11-27","current":-4.693302,"twenty":-107.266323,"median":-16.82571,"eighty":-10.023842,"marketCap":572183865},{"date":"2020-12-04","current":-5.154731,"twenty":-107.076745,"median":-16.687248,"eighty":-9.854869,"marketCap":628438979},{"date":"2020-12-11","current":-4.917695,"twenty":-105.889985,"median":-16.387138,"eighty":-9.709806,"marketCap":599540804},{"date":"2020-12-18","current":-4.566883,"twenty":-104.589811,"median":-16.249595,"eighty":-9.55943,"marketCap":556771505},{"date":"2020-12-24","current":-5.451815,"twenty":-104.095519,"median":-16.165272,"eighty":-9.409051,"marketCap":664658025},{"date":"2020-12-31","current":-5.548171,"twenty":-103.7856,"median":-16.084843,"eighty":-9.356272,"marketCap":676405290},{"date":"2021-01-08","current":-6.24683,"twenty":-103.682293,"median":-16.047123,"eighty":-9.312007,"marketCap":761582253},{"date":"2021-01-15","current":-6.398575,"twenty":-100.10529,"median":-15.937064,"eighty":-9.103551,"marketCap":780082226},{"date":"2021-01-22","current":-6.145667,"twenty":-99.961608,"median":-15.892056,"eighty":-8.895813,"marketCap":749248937},{"date":"2021-01-29","current":-7.783246,"twenty":-97.402399,"median":-15.801265,"eighty":-8.754011,"marketCap":948894487},{"date":"2021-02-05","current":-7.669438,"twenty":-96.771577,"median":-15.794033,"eighty":-8.573107,"marketCap":935019507},{"date":"2021-02-12","current":-7.916023,"twenty":-95.089059,"median":-15.752497,"eighty":-8.34596,"marketCap":965081964},{"date":"2021-02-19","current":-7.321689,"twenty":-94.863663,"median":-15.689009,"eighty":-8.317351,"marketCap":892623733},{"date":"2021-02-26","current":-6.232791,"twenty":-66.335484,"median":-15.634957,"eighty":-8.242791,"marketCap":787513195},{"date":"2021-03-05","current":-5.462858,"twenty":-58.586174,"median":-15.443898,"eighty":-8.105137,"marketCap":690232153},{"date":"2021-03-12","current":-5.921152,"twenty":-57.684242,"median":-15.368744,"eighty":-7.967182,"marketCap":748137535},{"date":"2021-03-19","current":-5.472024,"twenty":-57.481306,"median":-15.272011,"eighty":-7.929694,"marketCap":691390261},{"date":"2021-03-26","current":-1.10296,"twenty":-57.453121,"median":-15.15839,"eighty":-7.912775,"marketCap":139358952},{"date":"2021-04-01","current":-1.044909,"twenty":-57.430573,"median":-15.090546,"eighty":-7.868137,"marketCap":132024270},{"date":"2021-04-09","current":-1.075462,"twenty":-57.317832,"median":-15.05546,"eighty":-7.762382,"marketCap":135884629},{"date":"2021-04-16","current":-0.99908,"twenty":-57.100804,"median":-14.937268,"eighty":-7.692043,"marketCap":126233732},{"date":"2021-04-23","current":-1.047964,"twenty":-56.889413,"median":-14.835197,"eighty":-7.678012,"marketCap":132410306},{"date":"2021-04-30","current":-1.032688,"twenty":-56.331342,"median":-14.705083,"eighty":-7.610838,"marketCap":130480127},{"date":"2021-05-07","current":-0.934919,"twenty":-55.69999,"median":-14.626221,"eighty":-7.472063,"marketCap":118126979},{"date":"2021-05-14","current":-0.913532,"twenty":-55.609796,"median":-14.564312,"eighty":-7.366935,"marketCap":115424728},{"date":"2021-05-21","current":-0.992642,"twenty":-55.311031,"median":-14.547785,"eighty":-7.207565,"marketCap":128998815},{"date":"2021-05-28","current":-0.992642,"twenty":-54.967169,"median":-14.524678,"eighty":-6.897112,"marketCap":128998815},{"date":"2021-06-04","current":-1.096351,"twenty":-54.933346,"median":-14.498696,"eighty":-6.521869,"marketCap":142476303},{"date":"2021-06-11","current":-1.117093,"twenty":-54.916435,"median":-14.430897,"eighty":-6.405137,"marketCap":145171800},{"date":"2021-06-18","current":-1.069683,"twenty":-54.843153,"median":-14.301194,"eighty":-6.301837,"marketCap":139010663},{"date":"2021-06-25","current":-1.043015,"twenty":-54.820605,"median":-14.212047,"eighty":-6.174119,"marketCap":135545023},{"date":"2021-07-02","current":-0.998568,"twenty":-54.707863,"median":-14.180465,"eighty":-6.136182,"marketCap":129768957},{"date":"2021-07-09","current":-1.06672,"twenty":-54.437283,"median":-14.144966,"eighty":-5.902298,"marketCap":138625592},{"date":"2021-07-16","current":-1.007458,"twenty":-54.324541,"median":-14.058053,"eighty":-5.810894,"marketCap":130924170},{"date":"2021-07-23","current":-1.11413,"twenty":-54.223074,"median":-14.024045,"eighty":-5.698645,"marketCap":144786729},{"date":"2021-07-30","current":-1.097704,"twenty":-54.110332,"median":-13.98391,"eighty":-5.470191,"marketCap":130128424},{"date":"2021-08-06","current":-1.091209,"twenty":-53.952494,"median":-13.919071,"eighty":-5.442414,"marketCap":129358434},{"date":"2021-08-13","current":-1.097704,"twenty":-53.851027,"median":-13.889426,"eighty":-5.320151,"marketCap":130128424},{"date":"2021-08-20","current":-0.977541,"twenty":-53.676278,"median":-13.790453,"eighty":-5.255905,"marketCap":115883597},{"date":"2021-08-27","current":-1.048989,"twenty":-53.636818,"median":-13.760862,"eighty":-5.228374,"marketCap":124353494},{"date":"2021-09-03","current":-1.107447,"twenty":-53.569173,"median":-13.658298,"eighty":-5.189415,"marketCap":131283410},{"date":"2021-09-10","current":-1.029504,"twenty":-53.462068,"median":-13.584672,"eighty":-5.161354,"marketCap":122043522},{"date":"2021-09-17","current":-1.042494,"twenty":-53.433883,"median":-13.536087,"eighty":-5.124649,"marketCap":123583504},{"date":"2021-09-24","current":-1.00677,"twenty":-53.377512,"median":-13.447608,"eighty":-5.053071,"marketCap":119348555},{"date":"2021-10-01","current":-0.945065,"twenty":-53.225311,"median":-13.410003,"eighty":-4.992729,"marketCap":112033643},{"date":"2021-10-08","current":-0.938569,"twenty":-53.152029,"median":-13.312869,"eighty":-4.917695,"marketCap":111263653},{"date":"2021-10-15","current":-0.997027,"twenty":-53.123844,"median":-13.286827,"eighty":-4.892143,"marketCap":118193569},{"date":"2021-10-22","current":-1.010018,"twenty":-53.056198,"median":-13.234018,"eighty":-4.817327,"marketCap":119733550},{"date":"2021-10-29","current":-1.013265,"twenty":-52.864538,"median":-13.100938,"eighty":-4.769378,"marketCap":120118546},{"date":"2021-11-05","current":-1.071723,"twenty":-52.808167,"median":-13.081322,"eighty":-4.745927,"marketCap":127048462},{"date":"2021-11-12","current":-1.218072,"twenty":-52.76307,"median":-13.056061,"eighty":-4.687672,"marketCap":124323785},{"date":"2021-11-19","current":-0.690115,"twenty":-52.729248,"median":-13.003769,"eighty":-4.654514,"marketCap":70437314},{"date":"2021-11-26","current":-0.622235,"twenty":-52.593958,"median":-12.969971,"eighty":-4.638316,"marketCap":63509054},{"date":"2021-12-03","current":-0.592066,"twenty":-52.509402,"median":-12.889701,"eighty":-4.566883,"marketCap":60429827},{"date":"2021-12-10","current":-0.659946,"twenty":-52.509402,"median":-12.822246,"eighty":-4.55361,"marketCap":67358088},{"date":"2021-12-17","current":-0.535499,"twenty":-52.312104,"median":-12.757755,"eighty":-4.509369,"marketCap":54656277},{"date":"2021-12-23","current":-0.60338,"twenty":-52.176814,"median":-12.749565,"eighty":-4.483457,"marketCap":61584537},{"date":"2021-12-31","current":-0.520415,"twenty":-51.804767,"median":-12.739128,"eighty":-4.391816,"marketCap":53116663},{"date":"2022-01-07","current":-0.494017,"twenty":-51.652565,"median":-12.729239,"eighty":-4.256638,"marketCap":50422340},{"date":"2022-01-14","current":-0.441221,"twenty":-51.545461,"median":-12.685823,"eighty":-1.250504,"marketCap":45033693}],"updateTime":1746105075786}}}